In vitro-in vivo correlation for nevirapine extended release tablets

Biopharmaceutics and Drug Disposition

Volumn 30, Issue 9, 2009, Pages 542-550

  Macha, Sreeraj ^a   Yong, Chan Loi ^a   Darrington, Todd ^a   Davis, Mark S ^a   MacGregor, Thomas R ^a   Castles, Mark ^a   Krill, Steven L ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Extended release; In vitro in vivo correlation; Nevirapine

Indexed keywords

NEVIRAPINE;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISSOLUTION; DRUG RELEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; NORMAL HUMAN; TABLET FORMULATION; TANDEM MASS SPECTROMETRY; ULTRAVIOLET RADIATION;

ANTI-HIV AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; HUMANS; LINEAR MODELS; MODELS, STATISTICAL; NEVIRAPINE; POLYMERS; SOLUBILITY; TABLETS; TANDEM MASS SPECTROMETRY;

EID: 73349133044     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.691     Document Type: Article

References (19)

1. Bacolla A, Shih C-K, Rose JM, et al. Amino acid substitutions in HIV-1 reverse transcriptase with corresponding residues from HIV-2. Effect on Kinetic Constants and Inhibition by Non-nucleoside Analogs. J Biol Chem 1993; 268: 16571-16577.
2. Cheeseman SH, Havlir D, McLaughlin MM, et al. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8: 141-151.
3. Raffi F, Reliquet V, Ferre V, et al. The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults. Antivir Ther 2000; 5: 267-272.
4. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 1998; 279: 930-937.
5. Skowron D, Leoung G, Hall DB, et al. Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine, and nelfinavir therapy in HIV-1-infected adults. J Acquir Immune Defic Syndr 2004; 35: 351-358.
6. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS 1999; 13: 1099-1107.
7. Hawkins T. Impact of once- and twice-daily dosing regimens on adherence and overall safety. AIDS Read 2004; 14: 320-325.
8. Kappelhoff BS, Huitema AD, van Leth F, et al. 2NN Study Group. Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study. HIV Clin Trials 2005; 6: 254-261.
9. Ribera E, Rodriguez-Pardo D, Rubio M, et al. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients. Antivir Ther 2005; 10: 605-614.
10. Anekthananon T, Ratanasuwan W, Techasathit W, Sonjai A, Suwanagool S. Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study. J Med Assoc Thai 2004; 87: 760-767.
11. van Heeswijk RP, Veldkamp AI, Mulder JW, et al. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS 2000; 14: F77-F82.
12. Hawi A, Bell G. Preformulation studies of nevirapine, a reverse transcriptase inhibitor. Pharm Res 1994; 11(Suppl): S236.
13. Lamson MJ, Sabo JP, MacGregor TR, et al. Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers. Biopharm Drug Dispos 1999; 20: 285-291.
14. Macha S, Yong C, MacGregor T, et al. Assessment of nevirapine bioavailability from targeted sites in the human gastrointestinal tract. J Clin Pharmacol 2009; published online 30 September 2009.
15. Guidance for Industry. Dissolution Testing of Immediate Release Solid Oral Dosage Forms. FDA, CDER, 1997.
16. Rowland LS, MacGregor TR, Campbell SJ, Jenkins R, Pearsall AB, Morris JP. Quantitation of five nevirapine oxidative metabolites in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B 2007; 856: 252-260.
17. Levy G. Effect of dosage form on drug absorption, a frequent variable in clinical pharmacology. Arch Int Pharmacodyn 1964; 52: 59-68.
18. Levy G, Hollister LE. Dissolution rate limited absorption in man: factors influencing drug absorption from prolonged-release dosage form. J Pharm Sci 1965; 54: 1121-1125.
19. Guidance for Industry. Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations. FDA, CDER, 1997.